JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

Boston Scientific Corp.

Fechado

SetorSaúde

101.13 -1.24

Visão Geral

Variação de preço das ações

24h

Atual

Mín

101.02

Máximo

101.42

Indicadores-chave

By Trading Economics

Rendimento

123M

795M

Vendas

398M

5.1B

P/E

Médio do Setor

59.135

37.461

Margem de lucro

15.708

Funcionários

53,000

EBITDA

155M

1.4B

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+25.06% upside

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-4.6B

149B

Abertura anterior

102.37

Fecho anterior

101.13

Sentimento de Notícias

By Acuity

30%

70%

68 / 371 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

Boston Scientific Corp. Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

22 de out. de 2025, 11:00 UTC

Ganhos

Boston Scientific Raises Outlook on Continued Cardiovascular Growth

17 de out. de 2025, 11:43 UTC

Aquisições, Fusões, Aquisições de Empresas

Boston Scientific to Buy Rest of Nalu Medical for $533 Million

23 de jul. de 2025, 11:16 UTC

Ganhos

Boston Sci 2Q Net Surges, Company Boosts '25 EPS View on Cardiology Demand

22 de out. de 2025, 10:32 UTC

Ganhos

Boston Scientific Sees 4Q Organic Sales Up 11%-13% >BSX

22 de out. de 2025, 10:32 UTC

Ganhos

Boston Scientific Sees 4Q Sales Up 14.5-16.5% >BSX

22 de out. de 2025, 10:31 UTC

Ganhos

Boston Scientific Sees 2025 Organic Sales Up About 15.5% >BSX

22 de out. de 2025, 10:31 UTC

Ganhos

Boston Scientific Sees 2025 Sales Up About 20% >BSX

22 de out. de 2025, 10:30 UTC

Ganhos

Boston Scientific Sees FY Adj EPS $3.02-Adj EPS $3.04 >BSX

22 de out. de 2025, 10:30 UTC

Ganhos

Boston Scientific 3Q Organic Sales Up 15.3% >BSX

22 de out. de 2025, 10:30 UTC

Ganhos

Boston Scientific 3Q Adj EPS 75c >BSX

22 de out. de 2025, 10:30 UTC

Ganhos

Boston Scientific Sees FY EPS $1.97-EPS $2.01 >BSX

22 de out. de 2025, 10:30 UTC

Ganhos

Boston Scientific Sees 4Q EPS 48c-EPS 52c >BSX

22 de out. de 2025, 10:30 UTC

Ganhos

Boston Scientific 3Q Sales $5.07B >BSX

22 de out. de 2025, 10:30 UTC

Ganhos

Boston Scientific 3Q EPS 51c >BSX

22 de out. de 2025, 10:30 UTC

Ganhos

Boston Scientific Sees 4Q Adj EPS 77c-Adj EPS 79c >BSX

17 de out. de 2025, 11:02 UTC

Aquisições, Fusões, Aquisições de Empresas

Boston Scientific to Make Upfront Cash Payment of About $533 Million for Nalu Equity it Doesn't Already Own >BSX

17 de out. de 2025, 11:02 UTC

Aquisições, Fusões, Aquisições de Empresas

Boston Scientific: Nalu Acquisition to Expand Neuromodulation Offerings for People Living With Chronic Pain >BSX

17 de out. de 2025, 11:01 UTC

Aquisições, Fusões, Aquisições de Empresas

Boston Scientific: Nalu Medical Focused on Developing Minimally Invasive Solutions for Chronic Pain >BSX

17 de out. de 2025, 11:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Boston Scientific Announces Agreement To Acquire Nalu Medical, Inc. >BSX

9 de set. de 2025, 12:58 UTC

Aquisições, Fusões, Aquisições de Empresas

Boston Scientific to Buy Elutia's Bioenvelope Business for $88M

9 de set. de 2025, 12:31 UTC

Aquisições, Fusões, Aquisições de Empresas

Elutia Announces Sale of BioEnvelope Business to Boston Scientific for $88M

23 de jul. de 2025, 10:32 UTC

Ganhos

Boston Scientific Sees 3Q Sales Up 17%-19%, Organic Sales Up 12%-14% >BSX

23 de jul. de 2025, 10:31 UTC

Ganhos

Boston Scientific Sees 2025 Sales Up 18%-19%, Organic Sales Up 14%-15% >BSX

23 de jul. de 2025, 10:30 UTC

Ganhos

Boston Scientific Sees FY EPS $1.89-EPS $1.93 >BSX

23 de jul. de 2025, 10:30 UTC

Ganhos

Boston Scientific 2Q Organic Sales Up 17.4% >BSX

23 de jul. de 2025, 10:30 UTC

Ganhos

Boston Scientific 2Q EPS 53c >BSX

23 de jul. de 2025, 10:30 UTC

Ganhos

Boston Scientific 2Q Sales $5.06B >BSX

23 de jul. de 2025, 10:30 UTC

Ganhos

Boston Scientific Sees 3Q Adj EPS 70c-Adj EPS 72c >BSX

23 de jul. de 2025, 10:30 UTC

Ganhos

Boston Scientific 2Q Adj EPS 75c >BSX

23 de jul. de 2025, 10:30 UTC

Ganhos

Boston Scientific Sees FY Adj EPS $2.95-Adj EPS $2.99 >BSX

Comparação entre Pares

Variação de preço

Boston Scientific Corp. Previsão

Preço-alvo

By TipRanks

25.06% parte superior

Previsão para 12 meses

Média 126.45 USD  25.06%

Máximo 140 USD

Mínimo 113 USD

Com base em 24 analistas de Wall Street que oferecem metas de preço de 12 meses para Boston Scientific Corp. - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

24 ratings

23

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

102.95 / 104.93Suporte e Resistência

Curto Prazo

Bullish Evidence

Médio Prazo

Weak Bearish Evidence

Longo Prazo

No Evidence

Sentimento

By Acuity

68 / 371 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Boston Scientific Corp.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
help-icon Live chat